Fibrinolytic Treatment of Acute MyocardialInfarction


Authors: M. Aschermann;  J. Horák;  V. Řezníček;  prof. MUDr. Jan Bělohlávek, Ph.D.;  O. Aschermann
Authors‘ workplace: II. interní klinika 1. LF UK a VFN, Praha
Published in: Čas. Lék. čes. 2003; : 582-585
Category:

Overview

Direct PTCA is a treatment of choice in patients with acute myocardial infarction with ST segment elevations(STEMI). Fibrinolysis remains important modality of treatment in these patients. Currently, there are more then 100 tissueplasminogen activator mutants available with different fibrin specificity. In a clinical practice, tissue-type plasminogenactivator (t-PA), recombinant tissue-type plasminogen activator (rt-PA), tenecteplase (TNK-tPA) and lanoteplase(n-PA) are most important examples. Fibrinolytic treatment in STEMI patients should be used in patients presenting infirst 4 hours after beginning of chest pain, when it is sure, that direct PTCA cannot be started within next 90 minutes.Concomittant therapy of acute STEMI patients consists of anticoagulans, antiplatelet and antiagregatory treatment.

Key words:
acute myocardial infarction, fibrinolysis, tissue-type plasminogen activator.

Full text is not available online.
If interested in a scan of this journal, contact NTO ČLS JEP.

Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management

Article was published in

Journal of Czech Physicians


2003 Issue 10

Most read in this issue
Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account